Charles River Labs share price logo

Charles River Labs

NYSE: CRL

Large Cap

$359.69

-16.41

(-4.36%)

as on

Charles River Labs Stock Performance

as on October 31, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $351.98
    $374.56
    downward going graph

    2.14%

    Downside

    4.13%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $146.20
    $379.63
    downward going graph

    59.36%

    Downside

    5.54%

    Upside

    downward going graph

Charles River Labs share price movements today

Previous Close
$376.10
Open
$372.00
Volume
960.0K
Market Cap
$18.0B
Day's Low - High
$351.98 - $374.56
52 Week Low - High
$146.20 - $379.63

Charles River Labs Historical Returns

1 Month Return
+ 27.49 %
3 Month Return
+ 60.3 %
1 Year Return
+ 109.98 %
3 Year Return
+ 128.6 %
5 Year Return
-16.18 %

Charles River Labs Stock Fundamentals & Key Indicators

Check Charles River Labs market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$18.0B

EPS (TTM)

-4.84

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.17%

PE Ratio (TTM)

-77.27

Industry PE ratio

19.61

PEG Ratio

0.81

EBITDA

220.5M

Revenue (TTM)

4.0B

Profit Margin

32.24%

Return On Equity TTM

-7.72%

Charles River Labs vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Charles River Labs with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$18.0B-16.18%-77.2732.24%0.00%
StrongBuy$61.2B280.55%-312.0765.30%0.00%
StrongBuy$51.2B15.02%35.6753.73%0.56%
StrongBuy$260.4B12.02%37.0841.44%0.26%
StrongBuy$164.7B-23.99%38.2558.59%0.65%

Stock Returns calculator for Charles River Labs Stock including INR - Dollar returns

The Charles River Labs stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Charles River Labs investment value today

Current value as on today

₹2,15,136

Returns

₹1,15,136

(+115.14%)

Returns from Charles River Labs Stock

₹1,00,821 (+100.82%)

Dollar Impact

₹14,315 (+14.32%)

Analyst Recommendation on Charles River Labs Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.3076923076923% of analysts recommend a 'BUY' rating for Charles River Labs. Average target price of $318.87

Charles River Labs Share Price Target

Get share price movements and forecasts by analysts on Charles River Labs.

What analysts predicted

-12.8%DOWNSIDE

Target Price

$318.87

Current Price

$359.69

Analyzed by

13 Analysts

High

$357

Target

$318.87

Low

$295

Charles River Labs target price $318.87, a slight downside of -12.8% compared to current price of $359.69. According to 13 analysts rating.

Indian Investors' Interest in Charles River Labs Stock

Search interest for Charles River Labs Stock has increased by 114% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:114% versus previous 30 day period

Charles River Labs Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
1,011
1,026
1,009
1,002
984
1,032
1,004
994
995
1,004
Gross Profit
344
353
349
284
317
357
338
307
279
363
Operating Income
125
151
117
-167
74
100
133
120
119
119
EBITDA
219
238
209
-86
184
220
197
-192
63
150
Interest Expense
35
32
30
28
27
29
25
23
26
30
Depreciation
85
86
88
102
120
119
85
78
67
67
Income Before Tax
99
119
91
-216
35
71
87
-294
-29
53
Income Tax Expense
24
25
20
-3
10
18
31
-17
-15
53
Net Income
67
89
68
-215
25
52
54
-276
-14
-1
Net Profit Margin
34.09%
34.47%
34.56%
28.35%
32.28%
34.59%
33.72%
30.96%
28.05%
36.19%

Charles River Labs Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,857
2,266
2,621
2,923
3,540
3,976
4,129
4,049
4,015
Gross Profit
700
840
958
1,073
1,334
1,462
1,502
1,331
1,225
Operating Income
288
331
351
432
589
650
617
227
507
EBITDA
457
507
563
768
820
986
1,032
581
410
Interest Expense
29
63
60
86
73
59
136
126
107
Depreciation
131
161
198
234
265
303
314
361
403
Income Before Tax
296
281
304
447
480
622
581
93
-99
Income Tax Expense
171
54
50
81
81
130
100
67
42
Net Income
123
226
252
364
390
486
474
10
-144
Net Profit Margin
37.73%
37.07%
36.56%
36.72%
37.70%
36.79%
36.39%
32.88%
30.52%

Charles River Labs Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
74
94
70
-213
25
52
55
-276
-14
0
Operating Cash Flow
129
193
251
159
171
204
213
147
41
179
Investing Cash Flow
-85
-61
-21
-76
-45
-37
-33
-73
-407
28
Financing Cash Flow
18
-285
-207
-75
-105
-226
-152
-51
347
-164
Change in Cash
54
-157
30
-6
26
-46
24
6
-17
42

Charles River Labs Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
125
227
254
365
398
492
480
25
-142
Operating Cash Flow
316
441
480
546
760
619
683
734
737
Investing Cash Flow
-72
-955
-681
-601
-1,437
-607
-563
-245
-209
Financing Cash Flow
-208
558
231
47
672
-42
-85
-550
-536
Change in Cash
46
30
42
-6
13
-5
43
-78
10

Global Institutional Holdings in Charles River Labs

Check out the Institutions with significant holdings in Charles River Labs.

Funds
Holdings
Vanguard
10.35%
VANGUARD INDEX FUNDS
9.60%
iShares
5.09%
Fidelity Contrafund
4.60%
SPDR
4.05%

Charles River Labs News & Key Events

  • img

    Today's Timeline - 27 October

    Tue, 05:30 PM

    -

    Charles River Laboratories to use Virtual Control Group in Ipsen's upcoming GLP study, promoting reduced animal use.

Insights on Charles River Labs

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 994.22M → 1.00B (in $), with an average increase of 0.5% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -276.55M → -1.48M (in $), with an average increase of 1332.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CRL stock has moved up by 27.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Natera, Inc. Common Stock has given 1061.1% return, outperforming this stock by 932.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Natera, Inc. Common Stock has given 125.6% return, outperforming this stock by 15.6%

About Charles River Labs

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
OrganisationCharles River Labs
Headquarters251 Ballardvale Street, Wilmington, MA, 01887, US
IndustryMedical - Diagnostics & Research
CEOBirgit Girshick

Key Management of Charles River Labs

Name

Title

Mr. Glenn G. Coleman CPA

Corporate Executive VP & CFO

Mr. Mark Mintz

Corporate EVP, Chief Information Officer & Global Shared Services

Mr. Todd Spencer

Corporate Vice President of Investor Relations

Dr. Brian F. Bathgate Ph.D.

Corporate Senior Vice President of European Safety Assessment

Ms. Kerry Dailey

Corporate Senior VP & Chief Legal Officer

Ms. Amy E. Cianciaruso

Corporate Senior Vice President, Chief Communications Officer & Government Relations

Ms. Birgit Girshick

CEO & Director

Mr. Michael Gunnar Knell

Corporate Senior VP & Chief Accounting Officer

Mr. Joseph W. LaPlume J.D.

Corporate Executive Vice President of Corporate Development & Strategy

Ms. Victoria L. Creamer

Corporate Executive VP & Chief People Officer

FAQs

What is Charles River Labs share price today?

Charles River Labs share price today is $359.69 as on at the close of the market. Charles River Labs share today touched a day high of $374.56 and a low of $351.98.

What is the 52 week high and 52 week low for Charles River Labs share?

Charles River Labs share touched a 52 week high of $379.63 on and a 52 week low of $146.20 on . Charles River Labs stock price today i.e. is closed at $359.69,which is 5.25% down from its 52 week high and 146.03% up from its 52 week low.

What is Charles River Labs's market capitalisation today?

Charles River Labs market capitalisation is $0.02T as on .

How to invest in Charles River Labs Stock (CRL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Charles River Labs on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Charles River Labs Stock (CRL) from India?

Indian investors can start investing in Charles River Labs (CRL) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in Charles River Labs stock (as per the Rupee-Dollar exchange rate as on ). Based on Charles River Labs share’s latest price of $359.69 as on October 31, 2026 at 1:29 am IST, you will get 0.0278 shares of Charles River Labs. Learn more about fractional shares .

What are the returns that Charles River Labs has given to Indian investors in the last 5 years?

Charles River Labs stock has given -16.18% share price returns and 27.1% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?